Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Dec 12, 2017Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...
Dec 11, 2017CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...
Dec 7, 2017CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...
-
Dec 5, 2017The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.
05 Dec 2017 Melbourne, Australia and Vancouver, Canada: CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and...
Dec 5, 2017The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...
-
Nov 23, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Nov 16, 2017
This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...
-
Nov 9, 2017Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
09 Nov 2017 KING OF PRUSSIA, Pa. — 09 November 2017 Global biotherapeutics leader CSL Behring announced that results were published in The Lancet Neurology from its PATH study (Polyneuropathy...
-
Nov 8, 2017
Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. 08 Nov 2017 New fill-and-finish facility...
-
Oct 29, 2017A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo
29 Oct 2017 KING OF PRUSSIA, Pa. — 29 October 2017 Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median...
-
Oct 24, 2017- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US - Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks
24 Oct 2017 KING OF PRUSSIA, Pa — 24 October 2017 Global biotherapeutics leader CSL Behring announced today that new data will be presented for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous...
Oct 17, 2017Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance...
-
Oct 12, 2017There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.
12 Oct 2017 KING OF PRUSSIA, Pa. — 12 October 2017 CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA)...
-
Sep 28, 2017AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A
28 Sep 2017 TOKYO — 28 September 2017 AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA® reduces the number of injections...
-
Sep 28, 2017CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.
28 Sep 2017 KING OF PRUSSIA, Pa. — 28 September 2017 The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio...
-
Sep 27, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Sep 19, 2017CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn StateCSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
19 Sep 2017 UNIVERSITY PARK, Pa. — 19 September 2017 Penn State today announced that CSL Behring a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the...
-
Sep 14, 2017Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
14 Sep 2017 EDINBURGH, UK — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that its “Join Together” campaign at the 2017 European Society for Immunodeficiencies...
-
Sep 14, 2017Privigen shown to improve functional abilities in patients with a rare neurological condition
14 Sep 2017 KING OF PRUSSIA, Pa. — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune...
-
Sep 7, 2017- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1” - RAPID and RAPID extension trial data to be featured in poster and oral presentations
07 Sep 2017 MARBURG, Germany — 07 September 2017 Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 11 September, during the...
-
Sep 6, 2017Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)
06 Sep 2017 EDINBURGH, Scotland — 06 September 2017 Global biotherapeutics leader CSL Behring today announced that as part of its participation as a platinum sponsor of the 2017 meeting of the...
-
Aug 8, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 7, 2017
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase...
-
Jul 25, 2017- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients - Comprehensive support program offered to patients
25 Jul 2017 KING OF PRUSSIA, Pa. — 25 July 2017 Global biotherapeutics leader CSL Behring today announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...
-
Jul 21, 2017FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
21 Jul 2017 KING OF PRUSSIA, Pa. — 21 July 2017 Global biotherapeutics leader CSL Behring today announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven...